Shuping Zhuang

Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade

Ting Chen, Yunyan Gu, Yan Xu, 2022, British Journal of Cancer.

A genetic map of the chromatin regulators to drug response in cancer cells

Ting Chen, Yunyan Gu, Min Zou, 2022, Journal of Translational Medicine.

Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome

Yunyan Gu, L. Qi, Haihai Liang, 2021, Computational and structural biotechnology journal.

A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level

Ting Chen, Yunyan Gu, Zhiqiang Chang, 2021, Molecular Therapy. Nucleic Acids.

Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer

Xia Li, Yunyan Gu, Min Zou, 2021, iScience.

Pan‐cancer multi‐omics analyses reveal crosstalk between the Hippo and immune signaling pathways in the tumor microenvironment

Ting Chen, Tong Zhu, Yunyan Gu, 2021, FEBS letters.

Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells

Yunyan Gu, Yang Hui, Zhangxiang Zhao, 2023, British Journal of Cancer.

Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway

Yunyan Gu, Haihai Liang, Tong Yu, 2023, JCI insight.

Up-regulated SPP1 increases the risk from IPF to lung cancer via activating the pro-tumor macrophages

Yunyan Gu, Zhangxiang Zhao, Kaidong Liu, 2023, Computational and structural biotechnology journal.